The Endocrine Society recently updated its guidance on primary prevention of atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes in those at metabolic risk.
The findings may reassure prescribers of dipeptidyl peptidase-4 inhibitors that the drug class does not significantly increase the risk of adverse pancreatic outcomes compared with other second-line therapies, study authors said.
The results highlight the potential benefit of targeting individuals with an elevated one-hour blood glucose level and, if supported by additional evidence, eventually replacing the two-hour test with a ... Our results highlight the potential benefit of
The results highlight the importance of psychosocial interventions for at-risk patients, they concluded.
The studied risk factors were HbA1c level, LDL cholesterol level, presence of albuminuria, smoking status, and blood pressure.
The findings underscore the urgency of early diagnosis of diabetes and the consequences of failing to achieve near-normal glycemia soon after patients are diagnosed, according to the study authors.
A study conducted in Australia found that general practitioners with specialization in diabetes care and subspecialist-led clinics reduced HbA1c levels by similar amounts in patients with complex type 2 diabetes.
In a retrospective observational study, patients with prediabetes were assigned to a risk category for diabetes based on presence and severity of insulin resistance, impaired beta-cell function, and hyperglycemia, then treated accordingly.
Among patients with coronary artery disease, severity and frequency of hypoglycemia were associated with increased levels of high-sensitivity cardiac troponin T, although the association was attenuated in adjusted analyses.
The guideline, developed by the Joint British Diabetes Societies for Inpatient Care, noted that many patients taking insulin will know more about their usual regimen than the medical and nursing staff responsible for their care.